Status and phase
Conditions
Treatments
About
This is an open label, multi-center, Phase 1/2 study evaluating the safety, tolerability, PK, PD, and preliminary efficacy (antitumor activity) of BBT-207. It will consist of 3 parts; dose escalation, recommended phase 2 dose selection, and dose expansion.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Histologically or cytologically confirmed Stage III (locally advanced) NSCLC not amenable to curative therapy or stage IV NSCLC.
Patients must have received treatment with at least 1 third-generation EGFR TKI (eg, Osimertinib, Lazertinib).
Confirmation that the tumor harbors an EGFR mutation as follows:
Documented partial or complete response (CR) or durable (at least 16 weeks) stable disease, based on the RECIST criteria, after treatment of an EGFR TKI.
Radiological documentation of disease progression or intolerance to a previous continuous (at least 30 days) treatment with an approved EGFR TKI therapy (including, but not limited to osimertinib, afatinib, dacomitinib, gefitinib, or erlotinib).
All patients must have documented radiological progression or intolerance to the last treatment administered prior to enrolling in the study.
Has Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
Adequate organ function test result.
All standard therapeutic options have been exhausted, refused by the patient, or are contraindicated; or the patient is deemed by the investigator not to be an appropriate candidate for standard-of-care treatment (as defined in the country of participation).
Exclusion criteria
Has symptomatic brain or spinal cord metastases with exceptions.
Any of the following cardiac conditions within the last 6 months from the first dose of study treatment:
<Prior or Concomitant Anticancer Therapy>
An EGFR TKI, including but not limited to osimertinib, afatinib, dacomitinib, gefitinib, or erlotinib within 8 days of the first dose of study treatment.
Small molecule targeted inhibitor other than EGFR inhibitor class or cytotoxic chemotherapy within 14 days, or biologic anticancer medicine (cytokines or antibodies, etc.) within 28 days (before the initiation of BBT-207 treatment) for the systemic treatment of advanced NSCLC.
Has toxicities from previous anticancer therapies that have not resolved to baseline levels or to CTCAE grade ≤1, with the exception of alopecia and peripheral neuropathy.
Has had radiotherapy within 14 days before the initiation of study treatment. Note: Palliative radiotherapy for pain can be administered at any time before the first dose of study treatment.
Primary purpose
Allocation
Interventional model
Masking
24 participants in 3 patient groups
Loading...
Central trial contact
Bridge Biotherapeutics, Inc.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal